Lab-designed chimeric protein shows beneficial effects in animal models of Alzheimer’s disease

A research team at the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has developed a new protein capable of improving memory and reducing tau protein levels in animal models of Alzheimer’s disease. The new compound—HEBE, generated by fusing three proteins—represents a new approach in the search for new strategies to tackle the disease.

Guidelines aim to include end users in neurotechnology development

“Neurotechnology” refers to a broad range of technologies designed to interface with the nervous system, with the aim of treating neurological disorders, enhancing cognitive function, and improving overall well-being. This can include devices like brain-computer interfaces, neurostimulation systems, and wearable sensors that monitor brain activity or physiological responses.

FDA clears sepsis test that significantly reduces life-or-death diagnosis time

Sepsis, a life-threatening organ dysfunction, is responsible for an estimated 1 in 5 deaths globally and 1 in 3 deaths that occur within a U.S. hospital. It happens due to a dysregulated immune response to infection, and its high mortality rate correlates to the difficulty in quickly diagnosing and appropriately addressing the origin of infection, be it bacterial, viral, or some other pathogen. Current methods can delay that life-or-death determination for as long as three days.